Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Investor Overview

Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Presentations
DateTitle
03/04/19
Download Documentation Investor Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
03/18/19vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 18, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common S... 
Printer Friendly Version
02/27/19vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 27, 2019-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential of azeliragon in patients with mild-Alzheimer’s Disease (AD) and type 2 diabetes and our progress to date with our Simplici-T1 trial in type 1 dia... 
Printer Friendly Version
01/16/19vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase (GK) activa... 
Printer Friendly Version
11/19/18vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City. A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com. vTv Therapeuti... 
Printer Friendly Version
Webcasts
There are currently no items available.
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.